SHANGHAI -- November 19, 2026 -- China's National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS) have added CARsgen's CAR T-cell therapy satri-cel to the 2026 Commercial Health Insurance Innovative Drug List (CHIIDL). The listing comes about five months after the National Medical Products Administration approved the product in June 2026.
Satri-cel (satricabtagene autoleucel, code CT041) targets Claudin18.2. The listed indication is Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have failed at least two prior lines of therapy. CARsgen trades in Hong Kong under stock code 2171.HK.
The list takes effect 48 days after its November 14 publication
The NHSA published the list on November 14 at a press conference in Suzhou. It becomes effective on January 1, 2027, which is 48 days later by our calculation. That is roughly six to seven months after the June approval.
CARsgen says satri-cel is the first CAR T-cell therapy for solid tumors on the CHIIDL since the list was established. According to the company, this extends multi-tiered insurance support for CAR T-cell therapy beyond hematologic malignancies.
Inclusion places satri-cel outside basic reimbursement
The CHIIDL covers innovative drugs that exceed the basic coverage mandate of the national basic medical insurance scheme and cannot yet be included in the basic reimbursement list. It provides a payment basis for commercial health insurance and mutual medical aid. Patients and hospitals therefore depend on those payers, not on basic insurance, for satri-cel coverage.
CARsgen says it will support the design and implementation of commercial insurance products and speed up access at healthcare institutions. That wording indicates the insurance products are still to be built. Founder, Chairman and CEO Dr. Zonghai Li said the company will work with insurers and healthcare institutions to widen diversified payment. The company did not disclose the price of satri-cel or the reimbursement terms.
Three studies target earlier treatment lines than the approved label
The approved indication covers patients after at least two failed therapy lines. CARsgen is running three studies outside that population:
- A Phase I trial of adjuvant therapy in pancreatic cancer in China (NCT05911217).
- An investigator-initiated trial (IIT) of consolidation treatment after adjuvant therapy in patients with resected gastric or gastroesophageal junction adenocarcinoma (NCT06857786).
- An IIT of sequential therapy after first-line treatment of the same cancers (NCT07179484).
The CHIIDL listing applies only to the indication named in the release, so patients in these studies fall outside it.